Drug Profile
Research programme: antibody therapeutics - Agenus/Boehringer Ingelheim
Latest Information Update: 23 Mar 2018
Price :
$50
*
At a glance
- Originator 4-Antibody; Boehringer Ingelheim
- Developer Agenus; Boehringer Ingelheim
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified